THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of formula I:



I

in which

R is O or S;

R^1 is independently selected from H, optionally substituted alkyl, optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted heterocyclyl; an antioxidant; a targeting moiety; CN; halo; CF_3; SO_3H; and OR^2, SR^2, SOR^2, SO_2R^2, NR^2R^3, $(CH_2)_nNR^2R^3$, $HCNOR^2$, $HCNNR^2R^3$, $CONR^2R^3$, $CSNR^2R^3$, $NCOR^2$, $NCSR^2$, COR^2, CO_2R^2 , CSR^2 or $SO_2NR^2R^3$ in which R^2 and R^3 are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting moiety and n is an integer of 1 to 10;

X is independently selected from CH, CO, N and NH;

Z is independently selected from CH, CO, N, NH and O;

Y is absent or together with the ring to which it is attached forms a 5- or 6-membered optionally substituted aryl or a 5- or 6-membered optionally substituted heterocyclyl;

m is an integer from 1 to 3; and

p is an integer from 1 to 4,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof to a subject in need thereof,

with the provisos that:

(i) at least one of X and Z is other than CH;

(ii) phanquinone or tautomers thereof are excluded i.e., when R is O, R^1 at position 7 is OH, X is CH and Y is absent, then Z is not  ;

(iii) when R is O, Y is absent, Z is CH, X is CH other than at position 3

where X is N, m is 2 and R^1 is 

at position 3, then R^1 at position 2 is not 

or  ; and

(iv) clioquinol i.e, when R is O, Y is absent, Z and X are CH and m is 2,
Then R^1 at position 5 is not chloro and R^1 at position 7 is not iodo.

2. A method according to claim 1, in which the compound of formula I is selected from the following:

 8-hydroxy-4(3H)-quinazolinones;

 8-hydroxy-quinazoline;

 8-hydroxy-quinoxaline;



[1,6]naphthyridin-8-ol;



9-hydroxypyrimido[1,6-a]pyrimidin-4-one;



8-hydroxy-cinnoline;



6-hydroxy-phenazine;



4-hydroxy-acridine;



4,7(4,10)-phenanthrolin-5-ol;





9-hydroxypyrido[1,2-a]pyrimidin-4-one;



pyrido[3,2-d]pyrimidin-4-ol;



pyrido[2-3-d]pyridazin-8-ol;



[1,7]naphthyridin-8-ol;



[1,5]naphthyridine-4,8-diol;



[1,5]naphthyridine-8-ol;



pyrido[3,4-b]pyrazin-8-ol;



pyrido[3,4-b]pyrazin-5-ol;



pyridol[4,3-d]pyrimidin-8-ol;



4-hydroxy-4a,8a-dihydro-pyrano[3,2,b]pyridin-2-one;



8-hydroxy-6*H*-[1,6]naphthyridin-5-one;



8-hydroxy-6H-[1,6]naphthyrin-5-one;



dibenzo[a,g]quinolizin-8-one; and



4-hydroxy-1*H*-pyrido[3,2-d]pyridin-2-one

in which R^1, m, n and p are as defined in claim 1 and q is an integer of 1 or 2.

3. A method according to claim 1 or claim 2 in which the compound of formula I is a compound of formula IA



IA

in which

R, R^1 and m are as defined in claim 1;

W is CH, N or NH;

U is CH, CO or N; and

Y' is absent or together with the ring to which it is attached forms a 6 membered N-containing optionally substituted heterocyclyl.

4. A method according to claim 3 in which the compound of formula IA is selected from the following:

(i) Formula Ia



Ia

in which R, R^1, m and q are as defined above;

(ii) Formula Ib



Ib

in which R, R^1, m and q are as defined in any one of claims 1 to 3;

(iii) Formula Ic



Ic

in which R, R^1, m and q are as defined in any one of claims 1 to 3;

(iv) Formula Id



Id

in which R, R^1, m and q are as defined in any one of claims 1 to 3;

(v) Formula Ie



in which R, R^1, m and q are as defined in any one of claims 1 to 3; and

(vi) Formula If



in which R^1 and m are as defined in any one of claims 1 to 3.

5. A method according to any one of claims 1 to 4 in which R in the compound of formula I is O.

6. A method according to any one of claims 1 to 5 in which R^1 in the compound of formula I is halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkyl, OR^2, SR^2, $(CH_2)_nNR^2R^3$, $CONR^2R^3$ and $NCOR^2$ in which n, R^2 and R^3 are as defined in any one of claims 1 to 3.

7. A method according to any one of claims 1 to 6 in which R^1 in the compound of formula I is fluoro, iodo, chloro, optionally substituted phenyl, an optionally substituted unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, optionally substituted C_{1-4} alkyl, optionally substituted C_{2-6} cycloalkyl, optionally substituted C_{1-6} alkoxy, optionally substituted thio, $CH_2NR^4R^5$ in which R^4 and R^5 are independently selected from H and C_{1-4} alkyl or $CONH(CH_2)_2R^6$ in which R^6 is optionally substituted heterocyclyl.

8. A method according to any one of claims 1 to 7 in which Y in the compound of formula I is an optionally substituted phenyl, an optionally substituted unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms or an optionally substituted saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms.

9. A method according to any one of claims 1 to 8, in which the compound of formula I is as follows:



1055



1061



1067



1049











1066





1064

1065





1053

1045



1070



1063



1069



1048







1026

10. A method according to any one of claims 1 to 9, in which the neurological condition is a neurodegenerative disorder.

11. A method according to claim 10, in which the neurodegenerative disorder is neurodegenerative amyloidosis.

12. A method according to claim 10 or claim 11, in which the neurodegenerative disorder is sporadic or familial Alzheimer's disease, amyotrophic lateral sclerosis, cataract, Parkinson's disease, Creutzfeldt-Jacob disease and its new variant associated with "mad cow" disease, Huntington's disease, dementia with Lewy body formation, multiple system atrophy, Hallerboden-Spatz disease, diffuse Lewy body disease, fatal familial insomnia, Gertsmann Straussler Sheinker disease, hereditary cerebral haemorrhage with amyloidosis-Dutch type, multiple sclerosis, tauopathies, motor neuron disease or prion diseases.

13. A method according to claim 12, in which the neurodgenerative disorder is Parkinson's disease.

14. A method according to any one of claims 10 to 12, in which the neurodegenerative disorder is an Aβ-related condition.

15. A method according to claim 14, in which the Aβ-related condition is Alzheimer's disease or dementia associated with Down syndrome or one of several forms of autosomal dominant forms of familial Alzheimer's disease.

16. A method according to any one of the preceding claims which slows, reduces or arrests the cognitive decline of the subject.

17. A method according to any one of the preceding claims, which further comprises separate, sequential or simultaneous administration of another medicament.

18. A method according to claim 17, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

19. A method according to any one of the preceding claims, in which the compound of formula I is administered orally, topically or parenterally.

20. Use of the compound of formula I as defined in any one of claims 1 to 9, in the manufacture of a medicament for the treatment, amelioration and/or prophylaxis of a neurological condition.

21. Use of a compound of formula I as defined in any one of claims 1 to 9 for the treatment, amelioration and/or prophylaxis of a neurological condition.

22. A compound of formula I as defined in claims 1 to 9 for use in the treatment, amelioration and/or prophylaxis of a neurological condition.

23. Use of the compound of formula I as defined in any one of claims 1 to 9, as a pharmaceutical.

24. Use according to claim 23, in which the pharmaceutical is a neurotherapeutic or neuroprotective agent.

25. Use according to claim 23 or claim 24, in which the pharmaceutical is an antiamyloidogenic agent.

26. A pharmaceutical or veterinary composition comprising the compound of formula I as defined above in any one of claims 1 to 9 and a pharmaceutically or veterinarily acceptable carrier.

27. A composition according to claim 26 which further comprises another medicament.

28. A composition according to claim 27, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

29. A compound of formula II which is a compound of formula I as defined in any one of claims 1 to 9, with the further proviso that at least one R^1 is other than H.

30. A compound of formula IA as defined in claim 3.

31. Compounds of the formulae Ia, Ib, Ic, Id, Ie and If as defined in claim 4.

32. A compound as defined in claim 9 excluding 1049, 1048, 1026 and 1045.

33. A process for the preparation of the compound of formula II defined in claim 29 as described herein.

34. A compound of the formula: